Why Mylan (MYL) Stock Is Dropping Today

NEW YORK (TheStreet) -- Mylan (MYL) shares are down -2.1% to $46.93 on Thursday after the company lowered the top line of its full year earnings guidance to $3.45 from $3.60, while also lowering its top line full year revenue guidance to $8 billion from $8.2 billion.

The pharmaceutical company reported second quarter earnings of 69 cents per diluted share, 3 cents short of analysts expectations, on revenue of $1.84 billion that fell short of the $1.9 billion analysts were expecting.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates MYLAN INC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate MYLAN INC (MYL) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

MYL Chart MYL data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Will Allergan's Deal With Tribe Hold Up?

Trading Mylan: Look Out for This Key Level

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids